Featured Studies

Researchers want to see if they can measure the amount of anti-cancer drug, Abemaciclib in a brain tumor and brain fluid after a patient has taken this drug for a few days. These findings can help explain how much drug gets into the brain and how drugs work to shrink high grade gliomas to improve outcomes for these patients.

Research study #00-N-0082 aims to develop improved MRI techniques for studying brain function. Information obtained will be used to develop better imaging methods that will, in turn, permit a greater understanding of normal and abnormal brain behaviors.

Researchers at the National Institutes of Health are investigating the role of Near-Infrared Spectroscopy (NIRS) technologies as a monitoring tool for measuring oxygen levels, blood flow, and the make-up of skin and muscle in patients with sickle cell disease (SCD). In this study, researchers will compare NIRS measurements in people with and without SCD.

Doctors at the National Institutes of Health (NIH) are conducting a research study to determine the viability and safety of early initiation of oral therapy with cyclosporine and eltrombopag in patients with severe aplastic anemia (SAA).

Myelodysplastic syndromes (MDS) are disorders caused by abnormal blood cell production, potentially leading to low cell counts and increased susceptibility to clotting and infections. Past research suggests that inflammation may trigger these abnormalities, and this study seeks to further understand and improve treatment strategies for MDS by investigating the role of inflammation in bone marrow cell development.

People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. The risks increase for heart attacks or stroke. No medications have been effective at reducing this risk in people with lupus. Researchers at NIH are testing whether a drug (anifrolumab) can improve blood vessel function and reduce blood vessel inflammation in people with (SLE). Participants do not pay for tests, treatments, or procedures.

After stem cell transplantation, some people develop hard-to-treat anemia (low red blood cells) or thrombocytopenia (low platelets). Cytopenia(s) or low blood cell counts make you weak, prone to bleeding and bruising, and dependent on blood product transfusions. Researchers at the National Institutes of Health (NIH) are testing the drug fostamatinib to see if it is safe to treat cytopenia(s) after stem cell transplantation. A physician referral is not required to participate.